Condition: Relapsed/Refractory Multiple Myeloma · Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
The purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.
This description comes directly from the study's public registry record.
Jing Yang · +86 010-56315401 · yangjing@sumgenbio.com
Always discuss trial participation with your own doctor first.
| Beijing Chaoyang Hospital of Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Guangzhou First People's Hospital | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Not Yet Recruiting |
| First Affiliated Hospital of Henan University of Science and Technology | Luoyang, Henan, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| The First Affiliated Hospital Of Soochow University | Suzhou, Jiangsu, China | Recruiting |
| Shanxi Provincial Hospital | Taiyuan, Shanxi, China | Recruiting |
| The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital) | Xi’an, Shanxi, China | Recruiting |
| Tianjin Cancer University Airport Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, Tianjin Municipality, China | Not Yet Recruiting |
| The Second Affiliated Hospital Zhejiang University School Of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06508983